The stock of Ventyx Biosciences Inc (VTYX) has seen a 42.14% increase in the past week, with a 9.53% gain in the past month, and a 15.00% flourish in the past quarter. The volatility ratio for the week is 8.14%, and the volatility levels for the past 30 days are at 6.71% for VTYX. The simple moving average for the last 20 days is 22.91% for VTYX stock, with a simple moving average of -28.79% for the last 200 days.
Is It Worth Investing in Ventyx Biosciences Inc (NASDAQ: VTYX) Right Now?
The 36-month beta value for VTYX is also noteworthy at 0.32. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VTYX is 53.83M, and at present, short sellers hold a 15.11% of that float. The average trading volume of VTYX on November 26, 2024 was 1.16M shares.
VTYX) stock’s latest price update
The stock price of Ventyx Biosciences Inc (NASDAQ: VTYX) has surged by 22.82 when compared to previous closing price of 2.06, but the company has seen a 42.14% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at 15.74% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.96% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 8.14%, as shares surge +1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.74% upper at present.
During the last 5 trading sessions, VTYX rose by +36.52%, which changed the moving average for the period of 200-days by -0.41% in comparison to the 20-day moving average, which settled at $2.0500. In addition, Ventyx Biosciences Inc saw 2.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Mohan Raju, who purchase 261,752 shares at the price of $2.01 back on Nov 25 ’24. After this action, Mohan Raju now owns 2,175,028 shares of Ventyx Biosciences Inc, valued at $524,944 using the latest closing price.
Mohan Raju, the CEO AND PRESIDENT of Ventyx Biosciences Inc, purchase 238,248 shares at $1.83 during a trade that took place back on Nov 22 ’24, which means that Mohan Raju is holding 1,913,276 shares at $434,946 based on the most recent closing price.
Stock Fundamentals for VTYX
Current profitability levels for the company are sitting at:
- -152.58 for the present operating margin
- -0.05 for the gross margin
The net margin for Ventyx Biosciences Inc stands at -141.75. The total capital return value is set at -0.57. Equity return is now at value -54.24, with -48.98 for asset returns.
Currently, EBITDA for the company is -207.99 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 113.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.52.
Conclusion
In summary, Ventyx Biosciences Inc (VTYX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
